Submitted by baileylynn_100964 on Fri, 02/12/2021 - 03:32

Low-dose naltrexone: tricking the body to heal itself

Exp Biol Med (Maywood)
September 2011

Researchers have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN) can suppress cell proliferative-related disorders such as cancer and autoimmune diseases. LDN causes a compensatory increase in an endogenous opioid, the opioid growth factor (OGF, [Met5]-enkephalin), and the OGF receptor (OGFr).